KarXT and VYVGART Hytrulo Win First-Time China NRDL Coverage for 2027
ZLAB sits 54% above its 52-week low of $15.96.
Summary
China's 2026 National Reimbursement Drug List adds KarXT for schizophrenia and VYVGART Hytrulo for anti-AChR antibody-positive gMG as first-time listings, with NUZYRA, QINLOCK and AUGTYRO renewed. Reimbursement takes effect January 1, 2027, so the two growth products move from out-of-pocket pricing to covered volume in China's public insurance system. That matters because Q3 product revenue fell 7% as reported and 11% on a constant-currency basis, and the company posted a $46.1 million net loss — NRDL status is the main lever for converting these launches into volume. The renewals protect the existing oncology and infectious disease base rather than adding to it. Watch the January 1, 2027 effective date for the first covered-quarter volume data.
At the time of this announcement, ZLAB was trading at $24.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $15.96 to $29.02. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.